Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actovegin in Post-Stroke Cognitive Impairment (ARTEMIDA)
NCT01582854Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2012
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of deproteinized calf blood extract in post-stroke cognitive impairment (PSCI), sponsored by Takeda. Started Jun 2012; status: completed.
02
Drugs
deproteinized calf blood extract
03
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on NCT01582854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582854.